Антибактериальные лекарственные средства. Методы стандартизации препаратов - Хабриев Р.У.
ISBN 5-255-04072-1
Скачать (прямая ссылка):
9. Craig W. A., Andes D. R. Correlation of the Magnitude of the AUC24/ MIC for 6 Fluoroquinolones against Streptococcus pneumoniaewith Survival and Bactericidal Activity in an Animal Model. — In: Abstracts of the 40th ICAAC, Toronto, Canada, Sept. 17—20, 2000. — Abs-289.
10. Lister P. D. Pharmacodynamics of Gatifloxacin Against Streptococcus pneumoniaein an in vitro Pharmacokinetic Model: Impact of AUC: MIC Ratios on Eradication // Antimicob Agents and Chemother. — 2002. - Vol. 46. - P. 69-74.
11. Craig W. A., Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media 11 Pediatr. Infect. Dis. J. — 1996. — Vol. 15. — P. 255-259.
12. Craig W. A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins 11 Diagn. Microbiol. Infect. Dis. — 1995. — Vol. 22. — P. 89-96.
13. Mandell G. L. (ed). Principles and Practice of infection Diseases. — ed.
4. - NY, 1995. - P. 233-264.
Mandell G. L. (ed). op. cit..
14 .Andes D., Craig W. A. In vitro activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: Application to breakpoint determination // Antimicrob Agents Chemother. — 1998. — Vol. 42. - P. 2375-2379.
15. Dudley M. N., Ambrose P. G. Monte Carlo Simulation of new cefotaxime, ceftriaxone and cefepime susceptibility breakpoints for S. pneumoniae, including strains with reduced susceptibility to penicillin. — In: Abstracts of the 42nd ICAAC, San Diego, CA, Sept. 27—30, 2002. — Abs-635.
16. Petermans W. MIC-based therapies. — BVIKM/SBIMC, Antewerpen, 8 nov 2002.
17. Lode H., Garau JGrassi C. et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-cla-vulanic acid and erythromycin 11 Eur. Respir. J. — 1995. — Vol. 8 (12). - P. 1999-2007.
18. O’Doherty B., Dutchman D. A., Pettit R., Maroli A. Randomized, dou-ble-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia // J. Antimicrob. Chemother. — 1997. — Vol. 40, Suppl. A. — P. 73—81.
141
19. Genne D., Siegrist H. H., Humair L. et al. Clarithromycin versus amoxi-cillin-clavulanic acid in the treatment of community-acquired pneumonia 11 Eur. J. Clin. Microbiol. Infect. Dis. - 1997. - Vol. 16 (11). -P. 783-788.
20. Poirier R., Chardon H., Beraud A. et al. Efficacy and tolerability of pris-tinamycin vs amoxicillin-clavulanic acid combination in the treatment of acute community-acquired pneumonia in hospitalized adults // Rev. Pneumol. Clin. - 1997. - Vol. 53 (6). - P. 325-331.
21. Tremolieres F., de Kock F, Pluck N., Daniel R. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia // Eur. J. Clin. Microbiol. Infect. Dis. - 1998. - Vol. 17 (6). - P. 447-453.
ll.Aubier М., Verster R., Regamey C. et al. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group // Clin. Infect. Dis. — 1998. — Vol. 26 (6). — P. 1312— 1320/45.
23. Roson B.y Carratala JTubau F. et al. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone // Microb. Drug. Resist. — 2001.— Vol. 7 (1).— P. 85-96.
24. Fogarty С. М., Cyganowski М., Palo W. A. et al. A comparison of cefdi-toren pivoxil and amoxicillin/clavulanate in the treatment of communi-ty-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study // Clin. Ther. — 2002. — Vol. 24 (11).- P. 1854-1870.
25. Hagberg L., Torres A., van Rensburg D. et al. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia // Infection. — 2002. — Vol. 30 (6). - P. 378-386.
26. Finch R., Schurmann D., Collins O. et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment // Antimicrob. Agents Chemother. — 2002. — Vol. 46 (6). - P. 1746-1754.
ll.Jardim J. R., Rico G., de la Roza C. et al.\ Grupo de Estudio Latinoa-mericano CAP. A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial // Arch. Bronconeumol. — 2003. — Vol. 39 (9). - P. 387-393.
28. Torres A., Muir J. F., Corris P. et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia // Eur. Respir. J. 2003 - Vol. 21 (1). - P. 135-143.
29.Ambrose P. G., Quintiliani R. Limitations of Single-Point Pharmacodynamic Analysis j j Pediatric Infectious Disease Journal. — 2000. — Vol.
19. - P. 769.
